Edgewise Therapeutics, Inc. (EWTX)
Health Care ยท Pharmaceutical Preparations
Edgewise Therapeutics, Inc. (EWTX) is listed on Nasdaq, where its shares have traded since March 26, 2021. SentiSense covers Edgewise Therapeutics, Inc. in the Health Care sector, and its Standard Industrial Classification is Pharmaceutical Preparations. Kevin Koch is its chief executive officer. The company reports 127 employees, and its corporate website is www.edgewisetx.com.
About Edgewise Therapeutics, Inc.
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is developing novel therapeutics for muscular dystrophies and serious cardiac conditions. The company's product candidates are Sevasemten, EDG-7500, EDG-003, and EDG-15400. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies, including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company's products are currently in different stages of their development, being developed to target key muscle proteins and modulators to address a broad array of muscle diseases.
Latest reported results
Edgewise Therapeutics, Inc. reported revenue of $0.00 for Q2 FY2026.
Institutional ownership
In 13F filings for the quarter ended June 30, 2026, 219 institutions reported holding EWTX, with 119.2 million shares worth $4.8 billion in aggregate. The largest reported holders were Orbimed Advisors, Paradigm Biocapital Advisors and RA Capital Management. Of the 5 largest reported holders, 3 added shares, 1 reduced its position and 1 held its position unchanged during the quarter.
More on EWTX
- EWTX sentiment: whether news and social coverage of Edgewise Therapeutics, Inc. leans bullish or bearish, and the stories driving it.
- EWTX ownership: all 219 reporting institutions, plus insider and congressional trades.
- EWTX financials: revenue, net income, operating margin and free cash flow through Q2 FY2026.
SentiSense also tracks daily options readings for Edgewise Therapeutics, Inc.: IV rank, put/call percentile, 25-delta skew and open-interest walls.
Frequently asked questions
What does Edgewise Therapeutics, Inc. do?
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is developing novel therapeutics for muscular dystrophies and serious cardiac conditions.
What sector is EWTX in?
SentiSense classifies Edgewise Therapeutics, Inc. in the Health Care sector, and its Standard Industrial Classification is Pharmaceutical Preparations.
Where does EWTX stock trade?
Edgewise Therapeutics, Inc. (EWTX) is listed on Nasdaq, where its shares have traded since March 26, 2021.
Who is the CEO of Edgewise Therapeutics, Inc.?
Kevin Koch is the chief executive officer of Edgewise Therapeutics, Inc..